Relmada Historical Balance Sheet

RLMD Stock

USD 3.02 0.12 4.14%

Trend analysis of Relmada Therapeutics balance sheet accounts such as Cash of 3.9 M, Cash And Short Term Investments of 58.5 M, Common Stock Total Equity of 25.7 K or Common Stock Shares Outstanding of 31.6 M provides information on Relmada Therapeutics' total assets, liabilities, and equity, which is the actual value of Relmada Therapeutics to its prevalent stockholders. By breaking down trends over time using Relmada Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Relmada Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Relmada Therapeutics is a good buy for the upcoming year.

Relmada Therapeutics Inventory

4.87 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.

About Relmada Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Relmada Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Relmada Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Relmada Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Relmada currently owns. An asset can also be divided into two categories, current and non-current.

Relmada Therapeutics Balance Sheet Chart

At present, Relmada Therapeutics' Inventory is projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.6 M, whereas Total Current Liabilities is forecasted to decline to about 9.2 M.

Total Assets Total Current Liabilities Cash Cash And Short Term Investments Liabilities And Stockholders Equity Short Term Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of Relmada Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Relmada Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Relmada Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Relmada Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash

Cash refers to the most liquid asset of Relmada Therapeutics, which is listed under current asset account on Relmada Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Relmada Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Relmada Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Relmada Therapeutics balance sheet. This account contains Relmada Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Relmada Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Liabilities And Stockholders Equity

The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.

Most accounts from Relmada Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Relmada Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.At present, Relmada Therapeutics' Inventory is projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.6 M, whereas Total Current Liabilities is forecasted to decline to about 9.2 M.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	15.1M	12.5M	12.2M	9.2M
Total Assets	223.3M	152.9M	97.6M	60.8M

Total Current Liabilities Total Assets

Relmada Therapeutics balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Retained Earnings Total Equity	Capital Surpluse	Other Stockholder Equity	Property Plant And Equipment Gross
Total Assets		0.17	0.96	-0.34	-0.64	0.95	0.33	1.0	-0.17	0.69	0.84	0.86	0.88	0.16	1.0	0.27	-0.29	0.81	-0.21	0.67	-0.4	-0.41	-0.73	0.78	0.75	-0.11
Total Current Liabilities	0.17		-0.05	-0.69	0.06	0.07	0.69	0.18	0.64	-0.1	0.01	0.01	0.1	1.0	0.17	0.74	0.65	-0.11	-0.27	-0.23	-0.42	-0.32	0.25	-0.14	-0.07	0.1
Total Stockholder Equity	0.96	-0.05		-0.19	-0.64	0.93	0.18	0.96	-0.22	0.7	0.84	0.85	0.85	-0.07	0.96	0.08	-0.44	0.82	-0.15	0.71	-0.28	-0.31	-0.78	0.8	0.75	-0.1
Net Debt	-0.34	-0.69	-0.19		-0.17	-0.28	-1.0	-0.33	-0.37	0.21	-0.29	-0.4	-0.56	-0.68	-0.34	-0.48	-0.35	-0.05	0.09	0.19	0.16	0.11	-0.14	0.15	0.1	-0.2
Retained Earnings	-0.64	0.06	-0.64	-0.17		-0.51	0.19	-0.65	0.27	-0.98	-0.24	-0.68	-0.43	0.07	-0.64	-0.08	0.37	-0.85	0.19	-0.85	0.34	0.34	0.75	-0.91	-0.98	0.14
Accounts Payable	0.95	0.07	0.93	-0.28	-0.51		0.27	0.95	-0.22	0.59	0.92	0.79	0.82	0.05	0.95	0.11	-0.4	0.77	-0.14	0.66	-0.3	-0.36	-0.74	0.75	0.64	-0.14
Cash	0.33	0.69	0.18	-1.0	0.19	0.27		0.32	0.37	-0.24	0.3	0.39	0.55	0.68	0.33	0.46	0.34	0.04	-0.09	-0.21	-0.15	-0.09	0.16	-0.17	-0.12	0.2
Cash And Short Term Investments	1.0	0.18	0.96	-0.33	-0.65	0.95	0.32		-0.16	0.7	0.83	0.85	0.87	0.16	1.0	0.28	-0.28	0.81	-0.22	0.67	-0.41	-0.42	-0.73	0.78	0.75	-0.11
Common Stock Total Equity	-0.17	0.64	-0.22	-0.37	0.27	-0.22	0.37	-0.16		-0.3	-0.24	-0.26	-0.17	0.65	-0.17	0.62	0.59	-0.32	-0.1	-0.38	-0.29	-0.31	0.41	-0.36	-0.29	-0.11
Common Stock Shares Outstanding	0.69	-0.1	0.7	0.21	-0.98	0.59	-0.24	0.7	-0.3		0.33	0.66	0.44	-0.11	0.69	0.07	-0.39	0.88	-0.21	0.89	-0.38	-0.4	-0.81	0.95	0.99	-0.16
Non Current Liabilities Total	0.84	0.01	0.84	-0.29	-0.24	0.92	0.3	0.83	-0.24	0.33		0.64	0.79	0.01	0.84	-0.03	-0.41	0.57	-0.18	0.46	-0.21	-0.21	-0.61	0.53	0.38	-0.08
Inventory	0.86	0.01	0.85	-0.4	-0.68	0.79	0.39	0.85	-0.26	0.66	0.64		0.92	0.0	0.86	0.1	-0.34	0.83	-0.16	0.64	-0.28	-0.24	-0.64	0.73	0.77	-0.04
Other Current Assets	0.88	0.1	0.85	-0.56	-0.43	0.82	0.55	0.87	-0.17	0.44	0.79	0.92		0.09	0.88	0.19	-0.25	0.68	-0.15	0.45	-0.28	-0.25	-0.52	0.54	0.56	-0.11
Total Liab	0.16	1.0	-0.07	-0.68	0.07	0.05	0.68	0.16	0.65	-0.11	0.01	0.0	0.09		0.16	0.72	0.64	-0.12	-0.28	-0.24	-0.41	-0.31	0.27	-0.15	-0.08	0.09
Total Current Assets	1.0	0.17	0.96	-0.34	-0.64	0.95	0.33	1.0	-0.17	0.69	0.84	0.86	0.88	0.16		0.27	-0.28	0.81	-0.22	0.67	-0.4	-0.41	-0.73	0.78	0.75	-0.11
Common Stock	0.27	0.74	0.08	-0.48	-0.08	0.11	0.46	0.28	0.62	0.07	-0.03	0.1	0.19	0.72	0.27		0.69	0.03	-0.22	-0.13	-0.63	-0.68	0.16	-0.04	0.1	-0.24
Other Current Liab	-0.29	0.65	-0.44	-0.35	0.37	-0.4	0.34	-0.28	0.59	-0.39	-0.41	-0.34	-0.25	0.64	-0.28	0.69		-0.48	-0.25	-0.59	-0.43	-0.33	0.66	-0.51	-0.37	0.09
Net Tangible Assets	0.81	-0.11	0.82	-0.05	-0.85	0.77	0.04	0.81	-0.32	0.88	0.57	0.83	0.68	-0.12	0.81	0.03	-0.48		-0.25	0.95	-0.4	-0.48	-0.93	0.94	0.9	-0.18
Property Plant And Equipment Net	-0.21	-0.27	-0.15	0.09	0.19	-0.14	-0.09	-0.22	-0.1	-0.21	-0.18	-0.16	-0.15	-0.28	-0.22	-0.22	-0.25	-0.25		-0.15	0.81	0.47	0.2	-0.21	-0.21	-0.05
Current Deferred Revenue	0.67	-0.23	0.71	0.19	-0.85	0.66	-0.21	0.67	-0.38	0.89	0.46	0.64	0.45	-0.24	0.67	-0.13	-0.59	0.95	-0.15		-0.28	-0.42	-0.96	0.95	0.87	-0.2
Non Current Assets Total	-0.4	-0.42	-0.28	0.16	0.34	-0.3	-0.15	-0.41	-0.29	-0.38	-0.21	-0.28	-0.28	-0.41	-0.4	-0.63	-0.43	-0.4	0.81	-0.28		0.86	0.26	-0.34	-0.39	0.23
Non Currrent Assets Other	-0.41	-0.32	-0.31	0.11	0.34	-0.36	-0.09	-0.42	-0.31	-0.4	-0.21	-0.24	-0.25	-0.31	-0.41	-0.68	-0.33	-0.48	0.47	-0.42	0.86		0.38	-0.38	-0.39	0.42
Retained Earnings Total Equity	-0.73	0.25	-0.78	-0.14	0.75	-0.74	0.16	-0.73	0.41	-0.81	-0.61	-0.64	-0.52	0.27	-0.73	0.16	0.66	-0.93	0.2	-0.96	0.26	0.38		-0.91	-0.8	0.17
Capital Surpluse	0.78	-0.14	0.8	0.15	-0.91	0.75	-0.17	0.78	-0.36	0.95	0.53	0.73	0.54	-0.15	0.78	-0.04	-0.51	0.94	-0.21	0.95	-0.34	-0.38	-0.91		0.95	-0.16
Other Stockholder Equity	0.75	-0.07	0.75	0.1	-0.98	0.64	-0.12	0.75	-0.29	0.99	0.38	0.77	0.56	-0.08	0.75	0.1	-0.37	0.9	-0.21	0.87	-0.39	-0.39	-0.8	0.95		-0.15
Property Plant And Equipment Gross	-0.11	0.1	-0.1	-0.2	0.14	-0.14	0.2	-0.11	-0.11	-0.16	-0.08	-0.04	-0.11	0.09	-0.11	-0.24	0.09	-0.18	-0.05	-0.2	0.23	0.42	0.17	-0.16	-0.15

Click cells to compare fundamentals

Relmada Therapeutics Account Relationship Matchups

Relmada Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.2M	118.2M	223.3M	152.9M	97.6M	60.8M
Total Current Liabilities	2.6M	12.6M	15.1M	12.5M	12.2M	9.2M
Total Stockholder Equity	7.6M	105.6M	208.3M	140.4M	85.4M	43.3M
Net Debt	(8.9M)	(2.5M)	(44.4M)	(5.4M)	(4.1M)	(4.3M)
Retained Earnings	(111.7M)	(179.3M)	(305.1M)	(462.1M)	(560.9M)	(532.9M)
Accounts Payable	924.4K	8.3M	11.2M	5.3M	3.5M	3.0M
Cash	9.2M	2.5M	44.4M	5.4M	4.1M	3.9M
Cash And Short Term Investments	9.2M	117.1M	211.9M	148.3M	96.3M	58.5M
Common Stock Total Equity	39.0K	14.5K	16.3K	30.1K	27.1K	25.7K
Common Stock Shares Outstanding	6.3M	15.6M	17.6M	29.6M	30.1M	31.6M
Liabilities And Stockholders Equity	10.2M	118.2M	223.3M	152.9M	97.6M	61.0M
Non Current Liabilities Total	2.7M	1.3M	8.3M	11.2M	5.3M	0.0
Inventory	459K	903.2K	11.3M	4.0M	4.6M	4.9M
Other Current Assets	(55.0)	903.2K	11.3M	4.0M	1.2M	1.6M
Total Liab	2.6M	12.6M	15.1M	12.5M	12.2M	9.4M
Total Current Assets	10.0M	118.1M	223.3M	152.9M	97.5M	60.6M
Common Stock	9.7K	16.3K	27.7K	30.1K	27.1K	16.5K
Other Current Liab	(45.0)	4.3M	3.9M	7.2M	8.7M	7.4M
Net Tangible Assets	115.7M	105.6M	208.3M	140.4M	161.5M	169.6M
Non Current Assets Total	235.4K	112.6K	28.3K	34.9K	43.1K	41.0K
Capital Surpluse	88.8M	119.2M	235.5M	602.5M	692.9M	727.5M
Other Stockholder Equity	119.3M	284.9M	513.3M	602.5M	646.2M	678.5M
Property Plant And Equipment Gross	7.2K	5K	1.3K	16.7K	15.0K	14.3K
Property Plant Equipment	12.1K	7.2K	5.0K	1.3K	1.1K	1.1K
Other Assets	190.8K	111.4K	28.3K	34.9K	31.4K	29.8K
Net Receivables	308.9K	79.5K	86.4K	512.4K	589.3K	618.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:

How To Invest In Relmada

Details

Is Relmada Stock a good investment?

Details

What is Relmada Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.86)

Return On Assets

(0.59)

Return On Equity

(1.00)

The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Relmada Historical Balance Sheet

Relmada Therapeutics Inventory

4.87 Million

About Relmada Balance Sheet Analysis

Relmada Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Cash

Cash And Short Term Investments

Liabilities And Stockholders Equity

Relmada Therapeutics balance sheet Correlations

Relmada Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Relmada Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Stockholder Equity	+ 0.96	Total Assets

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Retained Earnings Total Equity	- 0.96	Current Deferred Revenue
Retained Earnings Total Equity	- 0.93	Net Tangible Assets
Capital Surpluse	- 0.91	Retained Earnings Total Equity